Abington Memorial Hospital's Rosenfeld Cancer Center Named Blue Distinction Center for Complex and Rare Cancers
ABINGTON, PA (March 17, 2008) - As part of its ongoing effort to give consumers information to improve health care decision-making, Independence Blue Cross announced that The Rosenfeld Cancer Center at Abington Memorial Hospital has been selected as one of the Delaware Valley's four Blue Distinction Centers for Complex and Rare Cancers (SM).
Abington Memorial Hospital received the Blue Distinction Center designation for its comprehensive inpatient cancer care programs delivered by multidisciplinary teams with subspecialty training and distinguished clinical expertise in treating complex and rare cancers, as well as, for its major surgical treatments for these rare types of cancer.
"On behalf of the physicians and staff at The Rosenfeld Cancer Center, we feel honored and privileged to be recognized for our work in rare and complex cancers," said John Redmond, III, M.D, director, The Rosenfeld Cancer Center at Abington Memorial Hospital. "We are committed to providing coordinated care with a team approach that utilizes all of the medical specialties important in the treatment of specific cancers."
Among other selection criteria, Abington Memorial Hospital met the following thresholds necessary to be named as a Blue Distinction Center for Complex and Rare Cancers for:
- depth of expertise across cancer disciplines in medicine, surgery, radiation oncology, pathology and radiology and has multidisciplinary team input, including sub-specialty trained teams for complex and rare cancers
- ongoing quality management and improvement programs for cancer care
- an ongoing commitment to using clinical data registries and providing access to appropriate clinical research for complex and rare cancers
- sufficient volume of experience in treating rare and complex cancers
Complex and rare cancers comprise approximately 15 percent of new cancer cases each year, making it difficult for patients to locate or research facilities with oncologic or surgical teams that are experienced in this specialty. The Blue Distinction designation helps identify these institutions.
"We are committed to strengthening the information we provide to members to help them make more informed decisions as this leads to better health outcomes," says Dr. I. Steven Udvarhelyi, chief medical officer at Independence Blue Cross. "The Blue Distinction program highlights for our members those hospitals with a strong track record of success in treating complex and rare cancers."
Blue Distinction Centers for Complex and Rare Cancers were developed in strategic collaboration with the National Comprehensive Cancer Network (NCCN) and with input from a panel of leading clinicians and professional organizations.
Blue Distinction® is a designation awarded by Blue Cross and Blue Shield companies to medical facilities that have demonstrated expertise in delivering quality healthcare. The designation is based on rigorous, evidence-based selection criteria established in collaboration with leading clinicians, medical societies and professional organizations.
"I am so proud that our program has earned the Blue Distinction Center designation," said Dr. Redmond. "It's further proof that the physicians and staff at The Rosenfeld Cancer Center are offering the best practices and highest standards of care."